Physician profile
Iris Dubetsky
NPI 1194895649
$2,495.08
in general payments reported to CMS, 2019-2025
27 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $558 · 2023: $468 · 2024: $652 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $457.95 | 2021-2025 | |
| Revance Therapeutics, INC. | $379.86 | 2024-2025 | Daxxify |
| Mayne Pharma Commercial LLC | $244.37 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.80 | 2021-2024 | Arazlo, Cabtreo |
| Abbvie INC. | $133.86 | 2021-2024 | |
| Lilly USA, LLC | $120.65 | 2021-2023 | Taltz, Olumiant |
| Journey Medical Corporation | $115.65 | 2022-2025 | |
| Incyte Corporation | $96.56 | 2021-2024 | Opzelura |
| Genzyme Corporation | $92.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $88.58 | 2021-2025 | Dupixent, Libtayo |
| Almirall LLC | $72.93 | 2021-2025 | Seysara |
| Kyowa Kirin, INC. | $52.46 | 2022-2023 | Poteligeo |
| Janssen Biotech, INC. | $51.93 | 2021-2024 | Tremfya |
| Merz North America, INC. | $51.47 | 2025 | |
| Dermavant Sciences, INC. | $47.06 | 2023 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $43.41 | 2023-2024 | Aklief, Oracea, Epsolay |
| Biofrontera INC. | $43.26 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $43.17 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $42.53 | 2022-2023 | Winlevi |
| Pfizer INC. | $34.58 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $30.13 | 2023 | |
| Organon LLC | $28.95 | 2025 | Nexplanon |
| Vyne Pharmaceuticals INC. | $24.04 | 2021 | |
| Allergan, INC. | $20.59 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.97 | 2024 | Ycanth |
| Epi Health, LLC | $14.48 | 2021 | |
| Genentech USA, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Dubetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.